OPEN ACCESS Freely available online

Immunological Disorders and Immunotherapy

Commentary

The Impact of Serological Variability on Lupus Nephritis: Membranous *vs.* Proliferative

Jamal Monkhouse*

Department of Infectious, Parasitic and Immune-Mediated, University of Pisa, Pisa, Italy

ABOUT TO STUDY

Lupus Nephritis (LN) is a serious kidney complication of Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease that causes inflammation in various organs. In lupus nephritis, the immune system attacks the kidneys, leading to inflammation and potential kidney failure if not properly managed. Lupus nephritis is categorized into different classes based on the underlying pathologic patterns observed in kidney biopsies. The two most commonly observed forms of lupus nephritis are Membranous Lupus Nephritis (MLN) and Proliferative Lupus Nephritis (PLN). While both forms involve kidney damage, their underlying mechanisms and clinical presentations can be quite different. Recent studies have shown that the serological markers, or blood-based immune markers, used to differentiate between these two forms of lupus nephritis are significantly distinct, providing valuable insights for diagnosis and treatment strategies.

Membranous *vs.* proliferative lupus nephritis

Lupus nephritis is classified into several classes based on histological findings from kidney biopsy. Membranous Lupus Nephritis (MLN) is characterized by thickening of the glomerular basement membrane, due to immune complex deposition, and is typically less associated with active kidney inflammation than proliferative forms. In contrast, Proliferative Lupus Nephritis (PLN), especially the more severe classes (e.g., Class III and IV), is marked by the proliferation of glomerular cells and inflammatory infiltrates, often leading to more significant kidney damage and dysfunction. PLN can cause rapid kidney deterioration if left untreated, whereas MLN may progress more slowly.

The pathogenesis of both forms involves the deposition of immune complexes, but the exact nature and progression of these complexes, as well as the inflammatory response they trigger, differ significantly. The differences in pathophysiology between membranous and proliferative lupus nephritis extend to their clinical manifestations and the serological markers that can be used to differentiate them.

Serological differences between membranous and proliferative lupus nephritis

Serological markers are essential tools in the diagnosis and management of lupus nephritis, as they reflect the systemic immune response and can help identify the underlying disease activity. Studies have shown that serologic profiles differ notably between patients with membranous and proliferative lupus nephritis, suggesting that these forms of the disease may be driven by different immunological mechanisms.

One of the key serological differences lies in autoantibodies, particularly anti-dsDNA (double-stranded DNA) antibodies and anti-C1q antibodies. Anti-dsDNA antibodies, which are highly specific to lupus, are typically found in higher titers in patients with proliferative lupus nephritis, especially in those with Class III and IV disease. These antibodies correlate with disease activity and are often associated with more severe kidney involvement. In contrast, anti-dsDNA antibodies are less commonly elevated in membranous lupus nephritis, where the autoimmune response may not be as directly linked to the glomerular injury seen in proliferative forms.

Additionally, anti-C1q antibodies, which target the C1q protein in the complement system, have been shown to have a strong association with proliferative lupus nephritis. Elevated levels of anti-C1q are frequently seen in patients with proliferative forms of lupus nephritis and are thought to contribute to immune complex deposition in the kidneys, which causes inflammation and tissue damage. These antibodies are not as commonly elevated in membranous lupus nephritis, further underscoring the differences in the immunological mechanisms driving each disease subtype.

In addition to these autoantibodies, complement levels specifically C3 and C4 are important serological markers in lupus nephritis. Low levels of complement, particularly C3, are often observed in patients with proliferative lupus nephritis, reflecting ongoing immune activation and the consumption of complement components as part of the immune complex-mediated inflammatory response. In contrast, complement levels tend to remain relatively preserved in membranous lupus

Correspondence to: Jamal Monkhouse, Department of Infectious, Parasitic and Immune-Mediated, University of Pisa, Pisa, Italy; E-mail: monkhouset@gmail.com

Received: 26-Dec-2024, Manuscript No. IDIT-24-36371; **Editor assigned:** 30-Dec-2024, PreQC No. IDIT-24-36371 (PQ); **Reviewed:** 13-Jan-2025, QC No. IDIT-24-36371; **Revised:** 26-Jul-2026, Manuscript No. IDIT-24-36371 (R); **Published:** 05-Aug-2026, DOI: 10.35248/2593-850.26.11.264

Citation: Monkhouse J (2026) The Impact of Serological Variability on Lupus Nephritis: Membranous *vs.* Proliferative. Immunol Disord Immunother. 11:264.

Copyright: © 2026 Monkhouse J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

nephritis, though they can still be affected in more severe cases. This difference in complement consumption is another distinguishing feature between the two forms of lupus nephritis.

CONCLUSION

The serological differences between Membranous Lupus Nephritis (MLN) and Proliferative Lupus Nephritis (PLN) are significant and provide essential clues for clinicians in diagnosing and managing lupus nephritis. While anti-dsDNA and anti-C1q antibodies are elevated in proliferative forms of the disease, reflecting higher disease activity and inflammation, these markers are less commonly involved in membranous lupus nephritis. Similarly, complement levels, particularly C3, are more likely to be reduced in PLN due to the increased immune complex deposition and inflammation. Understanding these serological differences not only aids in distinguishing between MLN and PLN but also plays a vital role in disease monitoring and treatment planning. With better recognition of the unique immunological features of each form, healthcare providers can offer more personalized and effective management for patients with lupus nephritis, improving outcomes and quality of life.